Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan

Journal of Gastroenterology

Volumn 39, Issue 10, 2004, Pages 969-974

  Suzuki, Fumitaka ^a   Arase, Yasuji ^a   Akuta, Norio ^a   Tsubota, Akihito ^a   Suzuki, Yoshiyuki ^a   Sezaki, Hitomi ^a   Hosaka, Tetsuya ^a   Someya, Takashi ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Matsuda, Marie ^a   Satoh, Junko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Genotype; HBeAg; HBV; Interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA INTERFERON; HEPATITIS B(E) ANTIGEN; INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HEPATITIS B; HUMAN; JAPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ALANINE TRANSAMINASE; ASIAN CONTINENTAL ANCESTRY GROUP; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; JAPAN; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; TREATMENT OUTCOME;

EID: 8544280731     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1430-x     Document Type: Article

References (28)

1. Beasley RP, Hwang LW, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981;II:1129-33.
2. Lok ASF, Heathcote EJ, Hoofnagel JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120: 1828-53.
3. Wong DHK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1993;119:312-23.
4. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alphainterferon therapy? Hepatology 1989;10:761-3.
5. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
6. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94.
7. Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomized controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; II:298-302.
8. Lok AS, Lai CL, Wu PC, Lau JV, Leung EK, Wong LS, et al. Alpha-interferon treatment in Chinese patients with chronic hepatitis B. J Hepatol 1990;11:121-5.
9. Yokosuka O, Omata M, Imazeki F, Okuda K, Summers J. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: Analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology 1985;5: 728-34.
10. Erhardt A, Heineke U, Blondien D, Gerlich WH, Adams O, Heintges T, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000;31:716-25.
11. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33:998-1002.
12. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, et al. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 2002;76:5985-92.
13. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, et al. Clinical characteristics of patients infected with hepatitis B virus genotypes A, B and C. J Gastroenterol 2002;37:35-9.
14. Usuda S, Okamoto H, Imawari H, Baba K, Tsuda F, Miyakawa Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in preS2-region product. J irol Methods 1999;80:97-112.
15. Gojobori T, Ishii K, Nei M. Estimation of average number of nucleotide substitutions when the rate of substitution varies with nucleotide. J Mol Evol 1982;18:414-23.
16. Saitou N, Nei M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;24:189-204.
17. Arase Y, Tsubota A, Saitoh S, Suzuki Y, Kobayashi M, Suzuki F, et al. Randomized, controlled trial of natural interferon-α therapy for e-antigen-positive chronic hepatitis B patients. Hepatol Res 2002;23:98-104.
18. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis B. J Hepatol 1990;11:S133-6.
19. Pastore G, Santantonio T, Milella A, Monno L, Mariano N, Moschetta R, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in serum: Response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992;20:221-5.
20. Fattovich G, Farci P, Rugge M, Brollo G, Mandas A, Pontisso P, et al. A randomized, controlled trial of lymphoblastoid interferon-alfa in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992;15:584-9.
21. Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997;26:1621-5.
22. Arase Y, Chayama K, Tsubota A, Murashima N, Suzuki Y, Koida I, et al. A randomized, double-blind, controlled trial of natural interferon-β therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels. J Gastroenterol 1996; 31:559-64.
23. Manesis E, Savas S, Petraki F, Papaioannou C, Tsiopou M, Hadziyannis S. Inteferon treatment and retreatment of HBeAg negative chronic hepatitis B: 12 years' follow up of 209 patients (abstract). Hepatology 1999;30:349A.
24. Wai CT, Chu CJ, Hussain M, Lok ASF. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36:1425-30.
25. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003;124:925-32.
26. Papatheodoridis GV, Manesis E, Hadziyannis SJ. Long-term follow up after initial response to interferon therapy in patients with HBeAg negative chronic hepatitis B (abstract). Hepatology 2000; 32:378A.
27. Lampertico P, Ninno ED, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37:756-63.
28. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003;46:182-9.